AstraZeneca today revised its data on its COVID-19 vaccine candidate, stating that its AZD1222 vaccine showed a 76% efficacy in preventing symptomatic COVID-19. 

The drug maker previously said its two-dose candidate is 79% effective in preventing symptomatic COVID-19. AstraZeneca also changed its estimated efficacy in people over 65, increasing it from 80% percent to 85%.

All revisions were attributed to “pre-specified interim analysis,” which had sparked concerns from the Data and Safety Monitoring Board, which monitors AstraZeneca’s phase 3 clinical trial.

Meanwhile, a South African study published in the New England Journal of Medicine on natural immunity and vaccine efficacy against the UK (B.1.1.7), South African (501Y.V2) and Brazilian (P.1) variants of SARS-CoV-2 found that the AstraZeneca vaccine may be much less effective against the South African variant.
 

Related News Articles

Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…